secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261798
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TERN-701 Phase 1 CARDINAL trial shows 75% cumulative MMR rate by 24 weeks in refractory CML; abstract at ASH
--------------------------------------------------------------------------------

- 75% (24/32) overall cumulative MMR rate by 24 weeks; 64% (14/22) achieved MMR, 100% (10/10) maintained MMR, no MMR loss.
- In difficult subgroups: 69% MMR in patients with lack of efficacy to last TKI, 60% with prior asciminib, 67% with prior asciminib/ponatinib/investigational TKI.
- Safety: 87% (48/55) remain on treatment; no DLTs; Grade 3+ TEAEs <10% (neutropenia 7%, thrombocytopenia 4%).
- Patients heavily pretreated: median 3 prior TKIs, 64% discontinued last TKI due to lack of efficacy, 36% had prior asciminib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000119312525261798/0001193125-25-261798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000119312525261798/d78407d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer